Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Allogene Therapeutics (ALLO) Capital Expenditures (2019 - 2025)

Allogene Therapeutics (ALLO) has disclosed Capital Expenditures for 7 consecutive years, with $279000.0 as the latest value for Q4 2025.

  • Quarterly Capital Expenditures rose 8.56% to $279000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $386000.0 through Dec 2025, down 44.38% year-over-year, with the annual reading at $386000.0 for FY2025, 44.38% down from the prior year.
  • Capital Expenditures hit $279000.0 in Q4 2025 for Allogene Therapeutics, up from -$36000.0 in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $19.0 million in Q3 2021 to a low of -$4.8 million in Q2 2021.
  • Historically, Capital Expenditures has averaged $1.3 million across 5 years, with a median of $257000.0 in 2024.
  • Biggest five-year swings in Capital Expenditures: soared 4985.35% in 2021 and later crashed 483.29% in 2022.
  • Year by year, Capital Expenditures stood at $736000.0 in 2021, then plummeted by 483.29% to -$2.8 million in 2022, then surged by 106.42% to $181000.0 in 2023, then skyrocketed by 41.99% to $257000.0 in 2024, then grew by 8.56% to $279000.0 in 2025.
  • Business Quant data shows Capital Expenditures for ALLO at $279000.0 in Q4 2025, -$36000.0 in Q3 2025, and $44000.0 in Q2 2025.